HPV vaccine push in schools could cut cancer risk for south african kids
NCT ID NCT05919901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a school-based communication strategy to help more children aged 9-12 in South Africa get the HPV vaccine, which prevents cancers caused by HPV. The program involves health materials and vaccine provision in schools. Researchers will measure how many children start and complete the vaccine series, aiming to reach those often missed by traditional healthcare.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPV vaccine
What this could lead to
If successful, this approach could increase HPV vaccination rates in vulnerable communities, potentially reducing cervical cancer risk.
What could go wrong
The trial is suspended, and it is a small early-stage feasibility study. Results may not apply broadly, and the intervention may not improve uptake as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Witwatersrand Health Consortium
Johannesburg, Gautang, South Africa